112 related articles for article (PubMed ID: 10636463)
21. Electroencephalographical effects of sarpogrelate hydrochloride versus ticlopidine hydrochloride in elderly patients with peripheral atherosclerosis.
Iwakuma H
J Int Med Res; 2004; 32(3):274-83. PubMed ID: 15174221
[TBL] [Abstract][Full Text] [Related]
22. Effects of sarpogrelate on serotonin-induced increases in cytosolic Ca2+ in cultured rat mesangial cells.
Kanamori A; Matoba K; Yajima Y
Life Sci; 1994; 55(18):PL365-70. PubMed ID: 7934648
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effects of H2-receptor antagonists on platelet function in vitro.
Nakamura K; Kariyazono H; Shinkawa T; Yamaguchi T; Yamashita T; Ayukawa O; Moriyama Y; Yotsumoto G; Toyohira H; Taira A; Yamada K
Hum Exp Toxicol; 1999 Aug; 18(8):487-92. PubMed ID: 10462360
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
[TBL] [Abstract][Full Text] [Related]
25. Effects of serotonin on platelet activation in whole blood.
Li N; Wallén NH; Ladjevardi M; Hjemdahl P
Blood Coagul Fibrinolysis; 1997 Nov; 8(8):517-23. PubMed ID: 9491270
[TBL] [Abstract][Full Text] [Related]
26. Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats.
Umrani DN; Bodiwala DN; Goyal RK
Mol Cell Biochem; 2003 Jul; 249(1-2):53-7. PubMed ID: 12956398
[TBL] [Abstract][Full Text] [Related]
27. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist.
Hara H; Osakabe M; Kitajima A; Tamao Y; Kikumoto R
Thromb Haemost; 1991 Apr; 65(4):415-20. PubMed ID: 2057925
[TBL] [Abstract][Full Text] [Related]
28. Syntheses and platelet aggregation inhibitory and antithrombotic properties of [2-[(omega-aminoalkoxy)phenyl]ethyl]benzenes.
Kikumoto R; Hara H; Ninomiya K; Osakabe M; Sugano M; Fukami H; Tamao Y
J Med Chem; 1990 Jun; 33(6):1818-23. PubMed ID: 2342076
[TBL] [Abstract][Full Text] [Related]
29. Multiple-Dose Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Subjects: A Comparison of Controlled-Release Sarpogrelate and Immediate-Release Sarpogrelate.
Lee SY; Kim JR; Jung JA; Kim TE; Lee SY; Huh W; Lee JW; Jun H; Ko JW
Pharmacology; 2015; 96(1-2):68-75. PubMed ID: 26089136
[TBL] [Abstract][Full Text] [Related]
30. The potentiation of adrenaline-induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects.
Alarayyed NA; Graham BR; Prichard BN; Smith CC
Br J Clin Pharmacol; 1995 Apr; 39(4):369-74. PubMed ID: 7640142
[TBL] [Abstract][Full Text] [Related]
31. Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease.
Satomura K; Takase B; Hamabe A; Ashida K; Hosaka H; Ohsuzu F; Kurita A
Clin Cardiol; 2002 Jan; 25(1):28-32. PubMed ID: 11808836
[TBL] [Abstract][Full Text] [Related]
32. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome.
Restituto P; Colina I; Varo JJ; Varo N
Am J Physiol Endocrinol Metab; 2010 May; 298(5):E1072-7. PubMed ID: 20197504
[TBL] [Abstract][Full Text] [Related]
33. Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes.
Yamada K; Niki H; Nagai H; Nishikawa M; Nakagawa H
J Pharmacol Sci; 2012; 119(3):243-50. PubMed ID: 22785018
[TBL] [Abstract][Full Text] [Related]
34. Collagen induced human platelet aggregation: serotonin receptor antagonism retards aggregate growth in vitro.
Menys VC
Cardiovasc Res; 1993 Nov; 27(11):1916-9. PubMed ID: 8287397
[TBL] [Abstract][Full Text] [Related]
35. Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates.
Ahmad S; Jeske WP; Walenga JM; Aldabbagh A; Iqbal O; Fareed J
Thromb Res; 2000 Oct; 100(1):47-54. PubMed ID: 11053616
[TBL] [Abstract][Full Text] [Related]
36. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo.
Gries A; Bode C; Peter K; Herr A; Böhrer H; Motsch J; Martin E
Circulation; 1998 Apr; 97(15):1481-7. PubMed ID: 9576429
[TBL] [Abstract][Full Text] [Related]
37. 3,3',5'-Triiodothyronine inhibits collagen-induced human platelet aggregation.
Masaki H; Nishikawa M; Urakami M; Yoshimura M; Toyoda N; Mori Y; Yoshikawa N; Inada M
J Clin Endocrinol Metab; 1992 Sep; 75(3):721-5. PubMed ID: 1517361
[TBL] [Abstract][Full Text] [Related]
38. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
39. The effects of a selective 5-HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers.
Millson DS; Jessup CL; Swaisland A; Haworth S; Rushton A; Harry JD
Br J Clin Pharmacol; 1992 Mar; 33(3):281-8. PubMed ID: 1576048
[TBL] [Abstract][Full Text] [Related]
40. 5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
Blood Coagul Fibrinolysis; 2005 Sep; 16(6):423-8. PubMed ID: 16093733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
